Yoshitaka Okamoto
Overview
Explore the profile of Yoshitaka Okamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
243
Citations
4274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jutel M, Zemelka-Wiacek M, Okamoto Y, Pfaar O
Allergy
. 2024 Dec;
80(3):904-907.
PMID: 39688144
No abstract available.
2.
Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data
Worm M, Demoly P, Okamoto Y, Vidal C, Daghildjian K, Yan K, et al.
World Allergy Organ J
. 2024 Jul;
17(7):100924.
PMID: 39035788
Background: The 300IR house dust mite (HDM) sublingual immunotherapy (SLIT) tablet is approved for treatment of HDM-induced allergic rhinitis (AR). To provide a comprehensive review of the 300IR HDM-SLIT tablet...
3.
Bousquet J, Schunemann H, Sousa-Pinto B, Zuberbier T, Togias A, Samolinski B, et al.
J Allergy Clin Immunol Pract
. 2024 Jul;
12(10):2648-2668.e2.
PMID: 38971567
The traditional healthcare model is focused on diseases (medicine and natural science) and does not acknowledge patients' resources and abilities to be experts in their own lives based on their...
4.
Devillier P, Demoly P, Gentil C, Bergmann K, Casale T, Okamoto Y, et al.
Clin Exp Allergy
. 2024 Mar;
54(5):329-338.
PMID: 38545699
Background: The symptoms of house dust mite (HDM)-induced allergic rhinitis (AR) vary with changes in exposure related to the weather or the domestic environment. In allergen immunotherapy (AIT) studies, a...
5.
Yonekura S, Okamoto Y, Yamaide F, Nakano T, Hirano K, Funakoshi U, et al.
Allergol Int
. 2024 Feb;
73(3):436-444.
PMID: 38350815
Background: This study aimed to clarify the diagnostic and predictive factors for perennial allergic rhinitis (PAR) onset in children by analyzing the results of the Chiba High-risk Birth Cohort for...
6.
Kurokawa T, Yonekura S, Gotoh M, Okano M, Maekawa Y, Okubo K, et al.
J Allergy Clin Immunol Glob
. 2023 Oct;
2(2):100075.
PMID: 37780797
Background: We previously demonstrated the efficacy of Japanese cedar (JC) pollen sublingual immunotherapy (SLIT) tablets for treating seasonal allergic rhinitis in a clinical trial (trial no. 206-2-1) that covered 5...
7.
Okamoto Y, Kato M, Ishii K, Sato Y, Hata T, Asaka Y
Immunotherapy
. 2023 Sep;
15(16):1401-1414.
PMID: 37727966
Data are limited for clinical outcomes with house dust mite (HDM) allergen immunotherapy beyond 2 years' observation. A post-marketing drug-use survey assessed the safety and effectiveness of the 300 index...
8.
Sousa-Pinto B, Louis G, Rodrigues J, Giuliano A, Baiardini I, Braido F, et al.
J Allergy Clin Immunol Pract
. 2023 Aug;
11(12):3742-3751.e9.
PMID: 37572753
Background: EQ-5D-5L (EuroQOL, 5 Domains, 5 Levels) is a widely used health-related quality-of-life instrument, comprising 5 domains. However, it is not known how each domain is impacted by rhinitis or...
9.
Larenas-Linnemann D, Mayorga-Butron J, Maza-Solano J, Emelyanov A, Dolci R, Miyake M, et al.
World Allergy Organ J
. 2023 Jul;
16(7):100800.
PMID: 37520611
Background: Diagnosis, classification, and treatment of allergic rhinitis (AR) varies considerably despite the availability of treatment guidelines. Objectives: We aimed to carry out a two-part modified Delphi panel study to...
10.
Iinuma T, Yonekura S, Hirahara K, Kurita J, Yoneda R, Arai T, et al.
Allergol Int
. 2023 May;
72(4):564-572.
PMID: 37147165
Background: Chronic rhinosinusitis is a common disease of the nasal cavity and is classified into two major endotypes, which are neutrophilic and eosinophilic. Some patients with neutrophilic and eosinophilic chronic...